SCHEMBL13243149

SCHEMBL13243149

CCCCOc1c(F)cc(CC(F)(F)C(=O)OCC)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 4/20 0.38
THRB P10828 4/20 0.38
FFAR4 Q5NUL3 2/20 0.36
FFAR1 O14842 1/20 0.36
RARA P10276 1/20 0.35
RARB P10826 1/20 0.35
CCNB2 O95067 2/20 0.35
CCNE2 O96020 2/20 0.35
CDK1 P06493 2/20 0.35
CDK4 P11802 2/20 0.35
CCNB1 P14635 2/20 0.35
CCND1 P24385 2/20 0.35
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
CCND2 P30279 2/20 0.35
CCND3 P30281 2/20 0.35
CCNB3 Q8WWL7 2/20 0.35
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK7 P50613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221551 0.81 ALDH1A1 (0.42) THRATHRBFFAR4FFAR1
SCHEMBL2306177 0.80 PTPN11 (0.40)
SCHEMBL13062424 0.78 THRA (0.48) THRATHRBRARARARBESR1
SCHEMBL13242469 0.75 ATM (0.41) THRATHRBCYP3A4
SCHEMBL12056222 0.75 FFAR4 (0.39) THRATHRBFFAR4RARARARB
SCHEMBL13242467 0.74 PPARA (0.41) THRATHRBRARARARBCCNB2
SCHEMBL13062425 0.73 THRB (0.68) THRATHRBFFAR4FFAR1RARA
SCHEMBL13242468 0.72 GRIN2D (0.40) THRATHRBFFAR4FFAR1RARA
SCHEMBL13242466 0.72 THRA (0.41) THRATHRBRARARARBCCNB2
SCHEMBL12056262 0.71 TUBB1 (0.40) THRATHRBCCNB2CCNE2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690095-A1 Aryl gpr120 receptor agonists and uses thereof Camabay Therapeutics, Inc. (US) 2014-01-29 EP disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 US disclosed
WO-2010048207-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR THRA 324/4885THRB 273/4885FFAR4 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.